- Open Access
Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis
Annals of Intensive Care volume 2, Article number: 31 (2012)
Vasculitis is characterized by the infiltration of vessel walls by inflammatory leukocytes with reactive damage and subsequent loss of vessel integrity. The clinical course of systemic vasculitis may be punctuated by acute life-threatening manifestations that require intensive care unit (ICU) admission. Furthermore, the diagnosis may be established in the ICU after admission for a severe inaugural symptom, mostly acute respiratory failure. Among the systemic vasculitides, cryoglobulinemic vasculitis (CV) has been rarely studied in an ICU setting. Severe CV-related complications may involve the kidneys, lungs, heart, gut, and/or central nervous system. The diagnosis of CV in the ICU may be delayed or completely unrecognized. A high level of suspicion is critical to obtain a timely and accurate diagnosis and to initiate appropriate treatment. We describe severe acute manifestations of CV based on six selected patients admitted to our ICU. That all six patients survived suggests the benefit of prompt ICU admission of patients with severe CV.
Vasculitis is defined by the presence of inflammatory leukocytes in vessel walls with reactive damage and subsequent loss of vessel integrity, which can lead to bleeding, tissue ischemia, and necrosis [1, 2]. The natural course of as-yet-undiagnosed and untreated systemic vasculitis may result in acute and life-threatening manifestations that require management in an intensive care unit (ICU) [3–8].
Cryoglobulinemic vasculitis (CV) is a small-vessel systemic vasculitis that results from the deposition of cryoglobulins on the vessel walls, activating the complement cascade [9–15]. Cryoglobulinemia is defined by the presence in the serum of one or more immunoglobulins (Igs) that undergo reversible precipitation at temperatures below 37°C [9–11, 15]. The 1974 Brouet classification distinguishes three cryoglobulin types based on the immunoglobulin composition of the cryoprecipitate (Additional file 1: Table S1) .
Clinically, the classical triad of purpura, weakness, and arthralgia is present in up to 80–90% of patients and may be associated with a broad spectrum of abnormalities, including other skin and joint manifestations, as well as involvement of the kidneys, digestive tract, peripheral nervous system, and salivary glands (Additional file 1: Table S2) [9–19]. Of note, serum cryoglobulins may be missed despite repeated testing and a typical cryoglobulinemic syndrome. Immune-complex-mediated, necrotizing, or leukocytoclastic small vessel-vasculitis is the pathological hallmark [9–11, 15].
The clinical course of CV is uneventful in more than 50% of patients [9–11, 15]. Fulminant, life-threatening flares are rare but must be diagnosed and treated promptly [20–23]. Widespread vasculitis, which is defined as involvement of the skin and at least two other organs, may develop (Table 1; Figure 1) [9–11, 15, 20–23]. In a retrospective study of 209 consecutive patients with CV, 29 patients had potentially life-threatening CV-related manifestations, of which 59% were present at onset . These manifestations were associated with a higher mortality rate and included renal failure due to cryoglobulinemic glomerulonephritis, intestinal vasculitis, pulmonary hemorrhage, and central nervous system involvement . The mortality rate reached 100% for patients with pulmonary hemorrhage or intestinal ischemia. The diagnosis of CV in the ICU may be delayed or be completely unrecognized. A high level of suspicion is critical to obtain a timely and accurate diagnosis and to initiate appropriate treatment. The scope of this review is to illustrate the potentially life-threatening nature of CV through the description of six selected patients admitted to our ICU. Written informed consent was obtained from the patient for publication of this report and any accompanying images. The clinical vignette of five patients is detailed, and one patient is only depicted in Figure 1. That all six patients survived argues strongly in favor of prompt ICU admission of patients with severe CV.
Two patients admitted to the ICU for acute respiratory failure due to CV-related renal involvement
Case 1 renal involvement
An 82-year-old female with an unremarkable medical history presented with recent onset of purpura, edema, and paresthesia with burning sensations in her extremities. Her condition worsened rapidly with acute respiratory distress and oliguria. At admission to the ICU, her blood pressure was 195/67 mmHg and she had bilateral crackles by lung auscultation. Chest computed tomography (CT) showed a bilateral pleural effusion and alveolointerstitial infiltrates (Figures 2a-b). Echocardiography indicated left ventricular diastolic dysfunction. The cryoglobulin test was positive for type II mixed cryoglobulinemia with a monoclonal IgM kappa. The serum C3 level was normal, but the serum C4 level was low. Serological tests for hepatitis C and B and human immunodeficiency virus were negative. A skin biopsy revealed leukocytoclastic vasculitis, and a kidney biopsy membranoproliferative glomerulonephritis (Figures 2c-d). The patient complained from xerostomia, and antinuclear and anti-SSA antibodies were positive. A minor salivary gland biopsy displayed a mononuclear cell infiltrate consistent with Sjögren’s syndrome. The diagnosis was primary Sjögren’s syndrome-related mixed cryoglobulinemia with peripheral neuropathy, skin lesions, and glomerulonephritis. The patient received oral prednisone (1 mg/kg/day) and four weekly infusions of rituximab (375 mg/kg/m² per week). She improved and her renal function recovered ad integrum.
Case 2 renal involvement
A 66-year-old female, with a history of type I CV due to a low-grade B-cell lymphoma 2 years before, was admitted to the ICU for acute respiratory failure. Her temperature was 36°C, heart rate 132 beats per minute, blood pressure 220/100 mmHg, and oxygen saturation 80%. The physical examination showed peripheral edema, purpura over the lower limbs, and bilateral lung crackles. She was rapidly intubated. Laboratory findings were as follows: hemoglobin, 8.8 g/dL; leukocyte count, 16,800/mm3; platelet count, 292,000/mm3; serum creatinine, 615 μmol/L; serum urea, 24 mmol/L; proteinuria in the nephrotic range; and hematuria. She experienced two episodes of nitroglycerin-responsive chest pain with slight troponin elevation and ST segment depression (Figure 3). The test for cryoglobulin was positive for type I cryoglobulinemia (IgG kappa), and the C4 level was low with undetectable total complement activity. These findings were consistent with a CV flare associated with low-grade B-cell lymphoma responsible for renal, skin lesions, and unstable angina. Steroids were initiated with daily plasma exchanges in addition to symptomatic treatment and hemodialysis. The patient was given low-dose aspirin and clopidogrel, combined with rituximab (375 mg/m²/week), and cyclophosphamide pulses (600 mg/m²/month). The cryoglobulin fell to undetectable levels. Her condition improved, but the renal function did not recover.
Renal involvement is the most common, severe, CV-related visceral manifestation, seen in more than one-third of cases [9–18]. Of 29 patients with life-threatening CV, 55% of the life-threatening episodes were due to CV-related glomerulonephritis . The renal symptoms typically consisted of mild proteinuria, microscopic hematuria, and hypertension [24–27]. More than 50% of patients had mild renal failure [24–27]. Nephrotic syndrome, nephritic syndrome, and acute kidney injury (AKI) have been reported in 20%, 14–25%, and 9% of patients, respectively [24, 26]. Fluid overload, oliguria, and metabolic disorders may require urgent renal replacement therapy, as illustrated by our second case [20, 23]. The main renal biopsy finding is type 1 membranoproliferative glomerulonephritis (70–80% of patients) [24–27]. Mesangial proliferative glomerulonephritis and focal and segmental glomerulonephritis also have been described [13, 24–26]. Renal failure may also result from nonglomerular lesions due to heart failure, sepsis, or hemorrhagic shock. The main short-term complications are AKI, oliguria, fluid overload with acute respiratory distress, and metabolic disorders. End-stage renal disease requiring long-term dialysis occurs in less than 15–30% of patients, and only after a course of 10 years in half of the cases [24, 25]. In a retrospective study of 105 patients with CV-related nephropathy and a mean disease duration of 11 years, factors predicting end-stage renal failure were age >50 years, splenomegaly, cryocrit >10%, low C3 level, recurrent purpura, initial serum creatinine >136 μmol/L, and HIV coinfection . Male gender may be correlated with a higher risk for requiring dialysis . In a series of 146 patients with cryoglobulinemic glomerulonephritis, age, serum creatinine, and proteinuria at the time of kidney biopsy correlated independently with end-stage renal failure . CV nephropathy may affect survival severely [9–11, 15, 19, 24–26]. Retrospective studies have pointed to renal involvement as a marker of poor prognosis [9–11, 15, 19, 24–26]. Interestingly, Terrier et al. have shown recently that a glomerular filtration rate <60 ml/min/1.73 m² at presentation, but not hematuria and proteinuria >1 g/day, was significantly associated with a poor prognosis in multivariate analysis . Of 105 patients with essential mixed cryoglobulinemia and renal involvement, 49% were alive 10 years after the renal biopsy—the main cause of death was cardiovascular disease—whereas 10-year survival after CV nephropathy onset was approximately 80% in a more recent study [24, 26]. Cardiovascular disease, infections, liver failure, non-Hodgkin’s lymphoma, and other malignancies were the main causes of death [19, 24–26].
Two patients admitted to the ICU for acute respiratory failure due to CV-related pulmonary or cardiac disease
Case 3 pulmonary disease
A 47-year-old male was referred to our hospital for exertional dyspnea and diffuse vascular purpura. At admission, his temperature was 36.7°C, his heart rate was 64 beats per minute, his blood pressure was 174/78 mmHg, and his oxygen satu-ration was 89%. Laboratory findings were as follows: hemoglobin, 7.8 g/dL; leukocyte count 3,600/mm3; platelet count, 179,000/mm3; serum creatinine, 278 μmol/L; serum urea, 24.6 mmol/L; and serum albumin, 30 g/L. The ratio of urinary protein to creatinine in random samples was 1,700 mg/mmol. Serological testing for HCV was positive. The serum C3 level was normal and the C4 level was 8 mg/dl (normal, 16–40). Rheumatoid factor was positive and serum type II cryoglobulinemia was found. The renal biopsy showed membranoproliferative glomerulonephritis. The patient received two weekly infusions of rituximab (375 mg/m²/week). Acute respiratory distress suddenly developed. At admission to the ICU, lung auscultation found bilateral crackles. The peripheral edema and skin lesions had worsened. Chest radiography and CT showed bilateral ground-glass opacities and alveolar infiltrates (Figure 4a-b). The bronchoalveolar lavage fluid contained 59·104 cells/mL with 84% macrophages of which 90% were hemosiderin-laden alveolar macrophages (Figure 4c). Cultures were negative. The diagnosis was CV-related pulmonary-renal syndrome with diffuse alveolar hemorrhage and membranoproliferative glomerulonephritis. He received three intravenous steroid pulses (1,000 mg/day) followed by oral prednisone (50 mg/day) in addition to intravenous cyclophosphamide pulses (600 mg/m²/month). A prompt improvement was noted with resolution of the purpura and partial recovery of renal function. Pegylated interferon alfa-2a and ribavirin therapy decreased the HCV load to undetectable levels. The cyclophosphamide was discontinued and the prednisone tapered.
Lung involvement in CV is mainly characterized by subclinical alveolitis, which occasionally leads to interstitial lung fibrosis [9, 29]. Although only scarce data are available in the literature, patent pulmonary involvement has been associated with poor survival in patients with CV . In the series by Ramos-Casals et al., the mortality rate reached 100% for patients with pulmonary hemorrhage . Acute severe pulmonary manifestations in patients with CV include (1) pulmonary edema, due to fluid overload caused by kidney and heart failure, (2) bronchopulmonary and systemic infections, (3) diffuse alveolar hemorrhage, and (4) hyperviscosity-related pulmonary lesions. Infections, although not specific of CV, may be precipitated by immunodeficiency related to the underlying disorder (most notably hematological malignancies) and drugs used to treat CV (steroids and immunosuppressive agents) [9–11, 15]. Retrospective studies indicate that infections are among the leading causes of death in patients with CV, after cardiovascular events [19, 24–26]. Acute respiratory distress is usually related to renal and/or heart failure with fluid overload and pulmonary edema, rather than to specific lung lesions, namely, diffuse alveolar hemorrhage and hyperviscosity-related pulmonary lesions [9, 12, 13, 15, 20, 23, 30–33]. Diffuse alveolar hemorrhage was the most common reason for ICU admission of patients with small-vessel vasculitis in the retrospective series of Khan et al., although none of the 28 patients displayed CV . Patients with diffuse alveolar hemorrhage generally present with acute hypoxemic respiratory failure or hemoptysis and anemia [5, 30–34]. Chest radiography and CT show diffuse pulmonary infiltrates, suggesting ongoing alveolitis [5, 30–34]. When performed, bronchoscopy usually reveals blood in the bronchoalveolar lavage fluid. The pathological examination may reveal intraalveolar red blood cells, fibrin, and eventually hemosiderin-laden macrophages, which may take up to 48 or 72 h to accumulate [30, 34]. Diffuse alveolar hemorrhage is associated with a wide spectrum of disorders, including systemic vasculitis and connective tissue disease . Diffuse alveolar hemorrhage occurs in less than 5% of patients with mixed cryoglobulinemia, irrespective of HCV status, and is generally associated with CV-related glomerulonephritis [30–33]. Therefore, CV should be on the list of differential diagnoses of pulmonary-renal syndrome [30, 34]. Our case contrasts with other reported cases, because diffuse alveolar hemorrhage is usually associated with a poor outcome . It is worth noting that the lung manifestations occurred shortly after the administration of rituximab, a drug whose reported adverse events include interstitial pneumonitis [35–37]. Interestingly, in patients with HCV-related CV, rituximab may form a complex with IgM kappa mixed cryoglobulin, thereby inducing an acute systemic flare of CV .
Case 4 cardiac disease
A 40-year-old female with chronic HCV infection was admitted to the ICU for acute bronchospastic respiratory distress. The temperature was 39.5°C, the heart rate was 170 beats per minute, the blood pressure was 200/120 mmHg, and the respiratory rate was 45 breaths per minute. The troponin level was slightly increased (0.13 μg/L, N < 0.02 μg/L), and the electrocardiogram showed T-wave inversion with normal ST segments. Endotracheal ventilation was started. Community-acquired pneumonia was suspected and empirical broad-spectrum antibiotic therapy was initiated. The patient also received bronchodilators and oral prednisone (1 mg/kg/day for 5 days). She improved and was extubated. However, she experienced an episode of abdominal pain and acute anemia (7.5 g/dL). Upper gastrointestinal endoscopy showed a cardial ulcer with no active bleeding. Skin ulcers developed over the legs, as well as nephrotic syndrome with peripheral edema and microscopic hematuria but no renal failure.
The diagnosis was HCV-related type II cryoglobulinemia involving the skin, joints, and kidneys, and probably the gut. Steroid therapy was resumed. Acute respiratory distress developed rapidly. The electrocardiogram showed T-wave inversion with normal ST segments. Endotracheal ventilation was initiated. A skin rash with purpura was noted after the administration of cold serum to measure cardiac output during Swan-Ganz catheter insertion. Echocardiography showed left ventricular diastolic dysfunction. The bronchoalveolar lavage fluid contained 26·104 cells/mL with 3.5% neutrophils and no hemosiderin-laden alveolar macrophages. Cultures were negative. The creatinine serum level increased to 127 μmol/l. Urinalysis showed hematuria and proteinuria in the nephrotic range. The diagnosis was respiratory failure due to CV-related heart failure precipitated by hypertensive crisis and renal involvement. Plasma exchanges were initiated in addition to symptomatic treatment. Replacement liquids were warmed before administration. Four weekly rituximab infusions (375 mg/m²/week) were administered. Ribavirin was added to pegylated interferon alfa-2a to control chronic HCV infection. The skin lesions resolved and the renal function recovered. Coronary angiography performed a few weeks later showed normal coronary arteries, suggesting involvement of the coronary microcirculation, which was consistent with CV-related heart involvement.
CV-related cardiac disease is a rare but life-threatening manifestation of CV [9, 16, 23, 39–41]. Systemic disease with respiratory distress and renal involvement is usually present in patients with CV-related cardiac disease. Acute cardiac involvement should be distinguished from long-term cardiovascular complications, which are among the leading causes of death in patients with CV [9, 16, 19, 23, 24, 26]. Moreover, the previous cardiovascular status should be considered . CV-related cardiac disease usually occurs concomitantly with other severe organ manifestations [39, 41]. Heart dysfunction with pulmonary edema is the main presentation. As reported in our patients, echocardiography may reveal diastolic and systolic dysfunction with low cardiac output and segmental dyskinesia or akinesia. Precipitating factors include: AKI; hypertensive crisis, which is usually severe and controllable only by using multiple antihypertensive medications; and coronary heart disease [9, 23]. Coronary heart disease is difficult to assess in patients with CV, because typical chest pain is not always present. The manifestations may consist only in mild troponin elevation or subtle changes in T waves or ST segments. CV-related coronary heart disease usually involves the coronary microcirculation, sparing the major arteries, which are usually normal by angiography . The etiologic and symptomatic treatment includes antiplatelet agents, anticoagulation, and beta blockers, in addition to steroids and plasma exchanges. Cardiac biomarkers and the electrocardiogram should be monitored closely until the symptoms resolve and the laboratory data return to normal. After treatment, the imaging studies, particularly the echocardiogram, should be repeated to assess heart function recovery, as illustrated by our case 4 .
Patient admitted to the ICU with severe gastrointestinal involvement
Case 5 gastrointestinal involvement
A 43-year-old female with a history of Sjögren’s syndrome-related type II cryoglobulinemia was hospitalized for recent onset of ulcers on her legs, acute abdominal pain, and peripheral edema. Urinalysis showed nephrotic-range proteinuria and hematuria, and the renal biopsy disclosed membranoproliferative glomerulonephritis. By abdominal CT, she had mild thickening of the left colonic wall consistent with ischemic colitis. Empirical antibiotics and three daily intravenous methylprednisolone pulses (1,000 mg/day) followed by prednisone (1 mg/kg/day) were administered. Her condition improved, and the steroids were tapered. Two weeks later, she experienced recurrent severe abdominal pain with high-grade fever. She was rapidly transferred to the ICU. Early colonoscopy showed numerous lesions of different ages, some of which were deep ulcerations without perforation, consistent with ischemic colitis. Empirical broad-spectrum antibiotics were initiated. Repeated physical examination demonstrated mild tenderness and peritoneal irritation over the left side of the lower abdomen. Emergency laparotomy revealed stercoral perforation of the colon. Colectomy followed by colostomy was performed. The pathological findings confirmed the diagnosis of CV-related ischemic colitis (Figure 5). In the meantime, mild dyspnea and a bilateral pleural effusion developed. The electrocardiogram and troponin levels were unchanged. Echocardiography indicated severe left ventricular dysfunction with septal akinesia. The diagnosis was a CV flare involving the skin, gut, kidneys, and heart. Intravenous cyclophosphamide pulse therapy (500 mg/m²) was added to the steroids and symptomatic treatment. A prompt improvement was noted, with resolution of the dyspnea and pleural effusion. She was discharged. Secondary bowel anastomosis was performed a few months later. Her cardiac abnormalities improved. Monthly intravenous cyclophosphamide pulses (500 mg/m²/month) were given for 9 months. The steroids were tapered to 5 mg/day and hydroxychloroquine was added to the long-term treatment regimen.
Gastrointestinal involvement is rare in patients with CV (5%) [9, 13, 15, 16, 19–21, 42–44]. CV may cause ischemic bowel disease, gastrointestinal hemorrhage, peritonitis, and acute lesions of any of the intraabdominal organs, including the pancreas and gallbladder [13, 20, 21, 42–44]. In a case-control study of 163 patients who had HCV-related CV and polyarteritis nodosa-like vasculitis, gastrointestinal involvement was observed in only four patients with histologicallydocumented CV . In patients with HCV-related systemic vasculitis, gastrointestinal lesions may be related to CV or polyarteritis nodosa-like vasculitis, although the test for serum cryoglobulin is usually positive . Pathological studies may assist in the differential diagnosis . Severe manifestations include acute surgical complications (peritonitis/perforation, mesenteric infarction, and cholecystitis), intestinal bleeding, and pancreatitis [20, 44]. Gastrointestinal lesions are associated with an increased likelihood of renal and cardiac involvement . Early diagnosis and management can lead to a favorable outcome, as in our case .
Other potentially life-threatening manifestations of cryoglobulinemic vasculitis
Neurological manifestations consist chiefly of peripheral neuropathy, particularly sensory and mixed polyneuritis [9–15, 45]. CV-related central nervous system manifestations, including stroke, brain hemorrhage, and encephalopathy, with impaired cognitive function are exceedingly rare [13, 16, 20, 45–50]. Spinal cord involvement has been described . The underlying mechanisms remain unclear but may involve either multiple, small, brain infarcts or small-vessel vasculitis .
Hyperviscosity syndrome due to high cryoglobulin levels is another rare but life-threatening complication of CV and is seen mainly in patients with lymphoproliferative disorders, chiefly Waldenström’s macroglobulinemia [9, 10, 12, 51]. The clinical presentation may combine acute respiratory distress, visual disturbances and retinal hemorrhage, encephalopathy with impaired cognitive function, and AKI [10, 51]. Hydration, steroids, and other immunosuppressive agents, as well as plasma exchange, should be initiated rapidly in patients with hyperviscosity syndrome [9–11, 15, 52, 53].
Liver failure is a major concern in patients with HCV-related CV [9–13, 15, 19, 20, 23, 24]. Acute-on-chronic liver failure or cirrhosis is the result of chronic active HCV infection rather than specific CV-related hepatic lesions [9, 10, 27].
Severe infections with septic shock may occur during the course of CV, particularly in patients receiving steroids and immunosuppressive agents or undergoing renal replacement therapy or plasma exchanges [19, 24, 26].
Management of severe acute CV-related manifestations
In clinical practice, particularly in the ICU, the management of life-threatening vasculitis is challenging [3, 4, 9]. A timely and accurate diagnosis is mandatory for the appropriate treatment to be implemented. The treatment has three targets: the symptoms, the cause, and the pathogenic mechanism [3, 4, 9–11, 15, 20, 23, 52]. In critically ill patients, the first-line treatment focuses on organ support and prevention of long-term organ dysfunction.
Treatments targeting the pathogenic mechanisms consist of steroids, immunosuppressive agents, and sometimes plasma exchange . These treatments should be tailored to disease severity, to the nature and extent of organ dysfunction in each individual patient [4, 9–11, 15, 52, 54]. Although no data from controlled, randomized, clinical trials are available, guidelines have been developed . In critically ill patients with CV, the first-line treatment aims at reversing the pathogenic mechanisms and consists of high-dose steroids (intravenous methylprednisolone pulses of 500–1000 mg/day for 3 days, followed by oral prednisone 1 mg/kg/day) and some of the time plasma exchanges (3 liters of plasma per exchange, three times a week for 2–3 weeks) [9–11, 15, 52, 53]. Immunosuppressive drugs—cyclophosphamide (2 mg/kg/day orally or 600 mg/m²/month intravenously for 2–4 months) or rituximab (375 mg/m²/week for 4 weeks)—should be considered promptly [9–11, 15, 52, 53]. Early plasma exchanges are mandatory in patients with hyperviscosity syndrome [9–11, 15, 52, 53]. Plasma exchanges aim at reducing the levels of circulating immune complexes, especially those containing cryoglobulins, whereas steroids and immunosuppressive agents help to reduce the production of cryoglobulins and to limit the inflammatory process in the blood vessel wall [9–11, 15, 52, 53]. Paradoxical precipitation of cryoglobulins has been reported after infusion of cold plasma, suggesting that replacement fluids for plasma exchange in CV should be warmed before infusion .
Identification of the underlying cause is mandatory and an etiology-based treatment is the mainstay of the long-term management [9–11, 15, 52, 53]. Interestingly, in the study by Ramos-Casals et al. that reported a high mortality rate in patients with life-threatening CV, most patients were HCV-positive and received immunosuppressant agents without antiviral therapy, which could have been deleterious . In case of HCV-related CV, the eradication of HCV infection is crucial [9–11, 15, 52, 53]. Antiviral therapy for 12 months consisting of standard or pegylated interferon-alpha combined with ribavirin is the reference standard and should be given whenever possible [9–11, 15, 52, 53]. Of note, ribavirin is best avoided if the glomerular filtration rate is <50 mL/min/1.73 m² to avoid hemolytic anemia . Moreover, it has been reported that interferon initiation during acute CV onset may result in paradoxical exacerbation of CV-related manifestations . Patients should be monitored closely for immune-mediated side effects of interferon therapy or ribavirin .
In a recent large study, Terrier et al. has showed that rituximab plus steroids had the greater therapeutic efficacy compared with steroids alone and alkalinating agents plus steroids to achieve complete clinical, renal, and immunological remission and a prednisone dosage <10 mg/day at 6 months . However, this regimen was associated with severe infections, particularly when high doses of corticosteroids were used, whereas death rates did not differ between the therapeutic regimens . Of note, only patients with underlying low-grade B-cell lymphoma or with refractory disease after rituximab and cyclosphamide as single agents should be administered combined rituximab plus cyclophosphamide therapy. Finally, patients with glomerulonephritis should receive angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and antihypertensive drugs to achieve the blood pressure and proteinuria targets established for patients with chronic kidney disease. This approach is crucial to minimize the long-term cardiovascular complications, which are the leading cause of death in patients with CV-related nephropathy [26, 52].
The natural course of systemic vasculitis may be punctuated by acute and life-threatening manifestations that require management in an intensive care unit (ICU). The diagnosis may be delayed or completely unrecognized. The six cases reported here illustrate the challenges raised by the diagnosis and management of a specific type of small-vessels vasculitis, i.e.,cryoglobulinemic vasculitis (CV), particularly in the ICU. CV usually runs a slow course, but acute flares with life-threatening manifestations may occur. A high level of suspicion is essential, and all CV patients should be monitored closely to ensure a timely and accurate diagnosis and to initiate appropriate treatment. Acute respiratory distress and AKI were the main reasons for ICU admission in our patients. Other serious manifestations that should be considered are involvement of the lungs, heart, central nervous system, and gut. Patients usually present with multiorgan failure, and the possibility of widespread vasculitis should be considered. Identification of the underlying cause is crucial, because adding etiology-based treatment to the life-supporting interventions and immunosuppressive therapy is likely to improve the outcome.
Acute kidney injury
Hepatitis C virus
Intensive care unit.
Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 1997,337(21):1512–1523. 10.1056/NEJM199711203372106
Watts RA, Scott DG: Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol 2009,23(3):429–443. 10.1016/j.berh.2008.12.004
Semple D, Keogh J, Forni L, Venn R: Clinical review: vasculitis on the intensive care unit–part 1: diagnosis. Crit Care 2005,9(1):92–97. 10.1186/cc3155
Semple D, Keogh J, Forni L, Venn R: Clinical review: vasculitis on the intensive care unit – part 2: treatment and prognosis. Crit Care 2005,9(2):193–197.
Khan SA, Subla MR, Behl D, Specks U, Afessa B: Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007,131(4):972–976. 10.1378/chest.06-2464
Diaz J, Calamia KT, Lee AS: Pulmonary vasculitis in the intensive care unit. J Intensive Care Med 2011,26(2):88–104. 10.1177/0885066610384551
Frausova D, Brejnikova M, Hruskova Z, Rihova Z, Tesar V: Outcome of thirty patients with ANCA-associated renal vasculitis admitted to the intensive care unit. Ren Fail 2008,30(9):890–895. 10.1080/08860220802353892
Holguin F, Ramadan B, Gal AA, Roman J: Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 2008,336(4):321–326. 10.1097/MAJ.0b013e31816805fa
Ferri C: Mixed cryoglobulinemia. Orphanet J Rare Dis 2008, 3: 25. 10.1186/1750-1172-3-25
Morra E: Cryoglobulinemia. Hematology Am Soc Hematol Educ Program 2005,2005(1):368–372. 10.1182/asheducation-2005.1.368
Tedeschi A, Barate C, Minola E, Morra E: Cryoglobulinemia. Blood Rev 2007,21(4):183–200. 10.1016/j.blre.2006.12.002
Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL: Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004,33(6):355–374. 10.1016/j.semarthrit.2003.10.001
Trejo O, Ramos-Casals M, Garcia-Carrasco M, Yague J, Jimenez S, de la Red G, Cervera R, Font J, Ingelmo M: Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001,80(4):252–262. 10.1097/00005792-200107000-00004
Brouet J, Clauvel J, Danon F, Klein M, Seligmann M: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974,57(5):775–788. 10.1016/0002-9343(74)90852-3
Ramos-Casals M, Stone JH, Cid MC, Bosch X: The cryoglobulinaemias. Lancet 2011.
Rieu V, Cohen P, André M, Mouthon L, Godmer P, Jarrousse B, Lhote F, Ferrière F, Dény P, Buchet P, Guillevin L: Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 2002,41(3):290–300. 10.1093/rheumatology/41.3.290
Bryce AH, Kyle RA, Dispenzieri A, Gertz MA: Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 2006,81(7):511–518. 10.1002/ajh.20643
Bridoux F, Provot F, Ayache RA, Goujon JM, Touchard G: Renal damage during type I cryoglobulinemia. Presse Med 2003,32(12):570–573.
Della Rossa A, Tavoni A, D'Ascanio A, Catarsi E, Marchi F, Bencivelli W, Salvadori S, Migliorini P, Bombardieri S: Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010,39(2):167–170. 10.3109/03009740903313639
Ramos-Casals M, Robles A, Brito-Zeron P, Nardi N, Nicolas JM, Forns X, Plaza J, Yague J, Sanchez-Tapias JM, Font J: Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006,36(3):189–196. 10.1016/j.semarthrit.2006.08.005
Mendez P, Saeian K, Reddy KR, Younossi ZM, Kerdel F, Badalamenti S, Jeffers LJ, Schiff ER: Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations. Am J Gastroenterol 2001,96(8):2489–2493.
Schwartzenberg S, Levo Y, Averbuch M: Generalized vasculitis, thrombocytopenia, and transient lymphoproliferative disorder caused by idiopathic mixed cryoglobulinemia. Am J Med Sci 2003,326(1):47–50. 10.1097/00000441-200307000-00007
Monti G, Saccardo F: Emergency in cryoglobulinemic syndrome: what to do? Dig Liver Dis 2007,39(Suppl 1):S112-S115.
Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L, et al.: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995,47(2):618–623. 10.1038/ki.1995.78
Beddhu S, Bastacky S, Johnson JP: The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002,81(5):398–409. 10.1097/00005792-200209000-00005
Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, Di Belgiojoso GB, Comotti C, Quarenghi MI: Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007,49(1):69–82. 10.1053/j.ajkd.2006.09.015
Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P: Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 2009,88(6):341–348. 10.1097/MD.0b013e3181c1750f
Terrier B, Carrat F, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Hummel A, Diot E, Pagnoux C, Lzaro E, Bridoux F, Zenone T, Hermine O, Leger JM, Mariette X, Senet P, Plaisier E, Cacoub P: Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2012. Epub ahead of print 10.1136/annrheumdis-2012-201405
Manganelli P, Salaffi F, Subiaco S, Carotti M, Cervini C, Consigli G, Majori M, Pesci A: Bronchoalveolar lavage in mixed cryoglobulinaemia associated with hepatitis C virus. Br J Rheumatol 1996,35(10):978–982. 10.1093/rheumatology/35.10.978
Amital H, Rubinow A, Naparstek Y: Alveolar hemorrhage in cryoglobulinemia–an indicator of poor prognosis. Clin Exp Rheumatol 2005,23(5):616–620.
Gomez-Tello V, Onoro-Canaveral JJ, de la Casa Monje RM, Gomez-Casero RB, Moreno Hurtrez JL, Garcia-Montes M, Armas LC: Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus-related mixed cryoglobulinemia. Intensive Care Med 1999,25(3):319–322. 10.1007/s001340050843
Johnston SL, Dudley CR, Unsworth DJ, Lock RJ: Life-threatening acute pulmonary haemorrhage in primary Sjogren's syndrome with cryoglobulinaemia. Scand J Rheumatol 2005,34(5):404–407. 10.1080/03009740510018741
Suzuki R, Morita H, Komukai D, Hasegawa T, Nakao N, Ideura T, Yoshimura A: Mixed cryoglobulinemia due to chronic hepatitis C with severe pulmonary involvement. Intern Med 2003,42(12):1210–1214. 10.2169/internalmedicine.42.1210
Lara AR, Schwarz MI: Diffuse alveolar hemorrhage. Chest 2010,137(5):1164–1171. 10.1378/chest.08-2084
Peerzada MM, Spiro TP, Daw HA: Pulmonary toxicities of biologics: a review. Anticancer Drugs 2010,21(2):131–139. 10.1097/CAD.0b013e328333d662
Lioté H, Lioté F, Séroussi B, Mayaud C, Cadranel J: Rituximab-induced lung disease: a systematic literature review. EurRespir J 2010,35(3):681–687.
Heresi GA, Farver CF, Stoller JK: Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008,76(4):449–453. 10.1159/000104866
Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P: Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009,60(12):3848–3855. 10.1002/art.25000
Bragagni G, Baldini A, Bianconcini M: Heart failure as clinical onset of essential mixed cryoglobulinemia. Minerva Med 1998,89(7–8):283–286.
Maestroni A, Caviglia AG, Colzani M, Borghi A, Monti G, Picozzi G, Cannatelli G: Heart involvement in essential mixed cryoglobulinemia. RicClin Lab 1986,16(2):381–383.
Karras A, Potier L, Reboux AH, Coldea N, Perdrix L, Jacquot C, Mousseaux E: Cryoglobulin-induced cardiomyopathy. J Am CollCardiol 2010,55(7):e13. 10.1016/j.jacc.2009.09.042
Befort P, Riviere S, Maran A, Ramos J, Lequellec A: Repeated intestinal tract perforations secondary to cryoglobulinemia and cytomegalovirus infection: a case report. Rev Med Interne 2010,31(2):167–169. 10.1016/j.revmed.2009.03.014
Fine GD, Trainer TD, Krawitt EL: Gastrointestinal bleeding, cryoglobulinemia, and hepatitis C. Am J Gastroenterol 2004,99(5):964–965. 10.1111/j.1572-0241.2004.40061.x
Terrier B, Saadoun D, Sène D, Scerra S, Musset L, Cacoub P: Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case–control study from a single-centre cohort of 163 patients. Gut 2010,59(12):1709–1715. 10.1136/gut.2010.218123
Maisonobe T, Leger JM, Musset L, Cacoub P: Neurological manifestations in cryoglobulinemia. Rev Neurol (Paris) 2002,158(10 Pt 1):920–924.
Casato M, Saadoun D, Marchetti A, Limal N, Picq C, Pantano P, Galanaud D, Cianci R, Duhaut P, Piette JC, Fiorilli M, Cacoub P: Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case–control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 2005,32(3):484–488.
Chen WH, Lin HS, Kao YF: Type II cryoglobulinemia and brain hemorrhage. ClinApplThrombHemost 2008,14(2):241–244.
Heckmann JG, Kayser C, Heuss D, Manger B, Blum HE, Neundorfer B: Neurological manifestations of chronic hepatitis C. J Neurol 1999,246(6):486–491. 10.1007/s004150050388
Mazzola L, Antoine JC, Camdessanche JP, Barral FG, Reynaud J, Michel D: Brain hemorrhage as a complication of type I cryoglobulinemia vasculopathy. J Neurol 2003,250(11):1376–1378. 10.1007/s00415-003-0190-5
Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R: Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998,315(3):208–210. 10.1097/00000441-199803000-00012
Della Rossa A, Tavoni A, Bombardieri S: Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations. SeminThrombHemost 2003,29(5):473–477.
Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008,73(109):S1-S99.
Rockx MA, Clark WF: Plasma exchange for treating cryoglobulinemia: a descriptive analysis. TransfusApherSci 2010,42(3):247–251.
Guillevin L, Pagnoux C: Indication for plasma exchange for systemic necrotizing vasculidities. TransfusApherSci 2007,36(2):179–185.
Evans TW, Nicholls AJ, Shortland JR, Ward AM, Brown CB: Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange. ClinNephrol 1984,21(5):287–293.
Campise M, Tarantino A: Glomerulonephritis in mixed cryoglobulinaemia: what treatment? Nephrol Dial Transplant 1999,14(2):281–283. 10.1093/ndt/14.2.281
Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, de Saint-Martin L, Quemeneur T, Huart A, Bonnet F, Le Guenno G, Kahn JE, Hinschberger O, Rullier P, Diot E, Lazaro E, Bridoux F, Zénone T, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Plaisier E, Cacoub P: Management of non-infectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012,119(25):5996–6004. 10.1182/blood-2011-12-396028
The authors declare that they have no competing interests.
MZ, EM, LG, BA, AM, and EA participated in the recruitment of the patients used to illustrate the review and in the design of the manuscript. VM and JV provided the illustrations and performed the pathological analysis of biopsy specimens. MZ, EM, AM, and EA drafted the initial manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Zaidan, M., Mariotte, E., Galicier, L. et al. Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. Ann. Intensive Care 2, 31 (2012). https://doi.org/10.1186/2110-5820-2-31
- Cryoglobulinemic vasculitis
- Acute respiratory failure
- Acute kidney injury
- Systemic disease